Clinical Trials Browser

Recurrence × Injections × 1 year × Clear all

NCT05564650 2026-05-19

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Phase 1 Completed

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT05294172 2026-05-08

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT06565689 2026-02-05

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012

Phase 1 Recruiting

Recurrence, Lymphoma, B-Cell

NCT06574568 2026-02-05

A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT04697940 2025-09-19

Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL

Phase 1/2 Active not recruiting

Recurrence, Lymphoma, B-Cell

NCT07011056 2025-09-19

A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma

Phase 3 Recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05554939 2025-08-06

Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL

Phase 1/2 Recruiting

Lymphoma, Non-Hodgkin, Recurrence

NCT04680988 2025-08-05

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

Phase 2 Completed

Uterine Cervical Neoplasms, Recurrence

NCT06838832 2025-07-30

Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL

Phase 1/2 Recruiting

Recurrence